Pediatric antifungal therapy.
The most common superficial dermatophyte infections in children involve the scalp, skin, and nails. Griseofulvin has traditionally served as the standard of care for scalp and nail infections, but an increasing proportion of tinea capitis infections are proving refractory or very slowly responsive to treatment. This article will review new antifungal therapies available and their future role in the treatment of pediatric dermatophyte infections. As these new agents are not yet FDA approved for use in the pediatric dermatophyte infections, the practitioner must be aware of possible risks and benefits of such drugs, and counsel families appropriately regarding "off-label" use.
Department of Medicine, University of California, San Diego School of Medicine, USA.
S F
SF
Friedlander
S
S
Suarez
D000935:Antifungal Agents / Q000627:therapeutic use*; D002648:Child; D003881:Dermatomycoses / Q000188:drug therapy*; D004347:Drug Interactions; D005260:Female; D015725:Fluconazole / Q000627:therapeutic use*; D006118:Griseofulvin / Q000627:therapeutic use*; D006801:Humans; D017964:Itraconazole / Q000627:therapeutic use*; D008297:Male; D009281:Naphthalenes / Q000627:therapeutic use*; D000077291:Terbinafine
D000935:Antifungal Agents; D009281:Naphthalenes; D017964:Itraconazole; D006118:Griseofulvin; D015725:Fluconazole; D000077291:Terbinafine